Nadya Jammal

Nadya Jammal

Auto-generated profile, based on publicly available information

Nadya Jammal

Department of Pharmacy University of Texas, MD Anderson Cancer Center Houston Texas USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
CRCaitlin R. Rausch
Caitlin R. Rausch
CDCourtney Dinardo
Courtney Dinardo
AMAbhishek Maiti
Abhishek Maiti
NJNadya J. Jammal
Nadya J. Jammal
TKTapan M. Kadia
Tapan M. Kadia
MKMarina Y. Konopleva
Marina Y. Konopleva


1 October 2020 in Expert Opinion on Emerging Drugs
Verified
Journal Article
Closed access
NJNadya Jammal
Nadya Jammal
CRCaitlin R. Rausch
Caitlin R. Rausch
TKTapan M. Kadia
Tapan M. Kadia
NPNaveen Pemmaraju
Naveen Pemmaraju
Introduction: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with poor long term outcomes. Cytotoxic chemotherapy remains the backbone of therapy especially among younger patients; however the effective incorporation of targeted therapies continues to be an area of active research in an effort to improve response durations and survival. Cell cycle inhibitors (CCI) are a novel class of agents which may be of particular interest for development in patients with AML. Areas covered: We will review the concept of CCIs and available pre-clinical and clinical data in the treatment of AML both in North America and abroad. Specific drug targets reviewed include cyclin D kinase, Aurora kinase, CHK1, and WEE1. Expert opinion: Utilization of CCIs in AML is an emerging approach that has shown promise in pre-clinical models. It has been challenging to translate this concept into clinical success due to marginal single-agent activity and toxicity profiles, however clinical evaluation remains ongoing. Addition of these agents to cytotoxic chemotherapy and other targeted therapies provides a potential combinatorial path forward for this novel class of therapies. Developing optimal combinations while balancing toxicity are among the top clinical challenges to overcome before we can anticipate adoption of these agents into the armamentarium of AML therapy.

15 January 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
IDIman Abou Dalle
Iman Abou Dalle
HKHagop M. Kantarjian
Hagop M. Kantarjian
FRFarhad Ravandi
Farhad Ravandi
Naval DaverNaval Daver
Naval Daver
XWXuemei Wang
Xuemei Wang
TKTapan M. Kadia
Tapan M. Kadia

1 December 2020 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Closed access
NJNadya Jammal
Nadya Jammal
SCSerena Chew
Serena Chew
EJElias Jabbour
Elias Jabbour
HKHagop Kantarjian
Hagop Kantarjian

1 December 2020 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Closed access
SCSerena Chew
Serena Chew
NJNadya Jammal
Nadya Jammal
HKHagop Kantarjian
Hagop Kantarjian
EJElias Jabbour
Elias Jabbour